PedAM
Pediatric Disease Annotations & Medicines
| facial paralysis | ||||
| Disease ID | 885 |
|---|---|
| Disease | facial paralysis |
| Manually Symptom | (Waiting for update.) |
| Text Mined Symptom | UMLS | Name | Sentences' Count(Total Symptoms:7) C0005745 | ptosis | 3 C0011849 | diabetes mellitus | 3 C0152226 | lagophthalmos | 2 C0015469 | facial paralysis | 1 C0586989 | varicella-zoster virus infection | 1 C0008373 | cholesteatoma | 1 C0035920 | rubella | 1 |
Manually Genotype(Total Text Mining Genotypes:0) |
|---|
| (Waiting for update.) |
All Snps(Total Genotypes:0) | |
|---|---|
| (Waiting for update.) | |
GWASdb Annotation(Total Genotypes:0) | |
|---|---|
| (Waiting for update.) | |
GWASdb Snp Trait(Total Genotypes:0) | |
|---|---|
| (Waiting for update.) | |
Mapped by lexical matching(Total Items:0) |
|---|
| (Waiting for update.) |
Mapped by homologous gene(Total Items:0) |
|---|
| (Waiting for update.) |
Chemical(Total Drugs:13) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| CUI | ChemicalName | ChemicalID | CasRN | DiseaseName | DiseaseID | DirectEvidence | PubMedIDs | ||
| C0015469 | albendazole | D015766 | 54965-21-8 | facial paralysis | MESH:D005158 | marker/mechanism | 17377173 | ||
| C0015469 | bupivacaine | D002045 | 2180-92-9 | facial paralysis | MESH:D005158 | marker/mechanism | 16275412 | ||
| C0015469 | cyclosporine | D016572 | 59865-13-3 | facial paralysis | MESH:D005158 | marker/mechanism | 12172772 | ||
| C0015469 | diatrizoate | D003973 | 117-96-4 | facial paralysis | MESH:D005158 | marker/mechanism | 5771816 | ||
| C0015469 | lidocaine | D008012 | 137-58-6 | facial paralysis | MESH:D005158 | marker/mechanism | 14689429 | ||
| C0015469 | methotrexate | D008727 | 1959/5/2 | facial paralysis | MESH:D005158 | marker/mechanism | 19738521 | ||
| C0015469 | mifepristone | D015735 | 84371-65-3 | facial paralysis | MESH:D005158 | marker/mechanism | 18460590 | ||
| C0015469 | omeprazole | D009853 | 73590-58-6 | facial paralysis | MESH:D005158 | marker/mechanism | 19617305 | ||
| C0015469 | paclitaxel | D017239 | - | facial paralysis | MESH:D005158 | marker/mechanism | 10586344 | ||
| C0015469 | phenytoin | D010672 | 57-41-0 | facial paralysis | MESH:D005158 | marker/mechanism | 11433844 | ||
| C0015469 | thalidomide | D013792 | 50-35-1 | facial paralysis | MESH:D005158 | marker/mechanism | 2019959 | ||
| C0015469 | vincristine | D014750 | - | facial paralysis | MESH:D005158 | marker/mechanism | 19770526 | ||
| C0015469 | vinorelbine | C030852 | 71486-22-1 | facial paralysis | MESH:D005158 | marker/mechanism | 16816907 | ||
FDA approved drug and dosage information(Total Drugs:4) | ||||||||
|---|---|---|---|---|---|---|---|---|
| DiseaseID | Drug_name | active_ingredients | strength | Dosage Form/Route | Marketing Status | TE code | RLD | RS |
| MESH:D005158 | prilosec | omeprazole | 20MG Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons | CAPSULE, DELAYED REL PELLETS;ORAL | Discontinued | None | Yes | No |
| MESH:D005158 | prilosec | omeprazole | 20MG Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons | CAPSULE, DELAYED REL PELLETS;ORAL | Discontinued | None | Yes | No |
| MESH:D005158 | omeprazole | omeprazole | 20MG | TABLET, DELAYED RELEASE;ORAL | Over-the-counter | None | Yes | Yes |
| MESH:D005158 | omeprazole | omeprazole | 20MG | TABLET, DELAYED RELEASE;ORAL | Over-the-counter | None | Yes | Yes |
FDA labeling changes(Total Drugs:4) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DiseaseID | Pediatric_Labeling_Date | Trade_Name | Generic_Name_or_Proper_Name | Indications Studied | Label Changes Summary | Product Labeling | BPCA(B) | PREA(P) | BPCA(B) and PREA(P) | Pediatric Rule (R) | Sponsor | Pediatric Exclusivity Granted Date | NNPS |
| MESH:D005158 | 12/7/2002 | prilosec | omeprazole | Gastroesophageal reflux and erosive esophagitis | Safety and effectiveness established in pediatric patients 2-16 years of age Information on dose, PK parameters, exposure/response and AE profile | Labeling | B | - | - | - | AstraZeneca | - | FALSE' |
| MESH:D005158 | 03/20/2008 | prilosec | omeprazole | Maintenance healing of erosive esophagitis | Efficacy was extrapolated from adults and older children to 1 to 2 year olds and supported with an open-label trial Unique adverse reactions in pediatric patients included increased respiratory system adverse events and fever. Safety and effectiveness in children less than 1 year of age have not been established Dosing and administration information provided for patients 1 year and older weighing at least 5 kg. New dosage form | Labeling | - | - | B, P | - | AstraZeneca | 1/5/2001 | FALSE' |
| MESH:D005158 | 12/7/2002 | prilosec | omeprazole | Gastroesophageal reflux and erosive esophagitis | Safety and effectiveness established in pediatric patients 2-16 years of age Information on dose, PK parameters, exposure/response and AE profile | Labeling | B | - | - | - | AstraZeneca | - | FALSE' |
| MESH:D005158 | 03/20/2008 | prilosec | omeprazole | Maintenance healing of erosive esophagitis | Efficacy was extrapolated from adults and older children to 1 to 2 year olds and supported with an open-label trial Unique adverse reactions in pediatric patients included increased respiratory system adverse events and fever. Safety and effectiveness in children less than 1 year of age have not been established Dosing and administration information provided for patients 1 year and older weighing at least 5 kg. New dosage form | Labeling | - | - | B, P | - | AstraZeneca | 1/5/2001 | FALSE' |